Article detail · 2011 · article
Cyanoacrylate for Septal Ablation in Hypertrophic Cardiomyopathy
Data source split
- YÖKSİSYÖKSİS article record
- YÖKSİS venueJournal of Interventional Cardiology
- Catalog match (ISSN)Journal of Interventional Cardiology
- OpenAlexOpenAlex enrichment (abstract, citations, topics)
- Semantic Scholarcitation count (not merged with OpenAlex)
Abstract
OBJECTIVE: Alcohol septal ablation (ASA) has been shown to be an effective treatment in patients with hypertrophic obstructive cardiomyopathy (HOCM) who are refractory to medical treatment. We describe an alternative approach for septal ablation with glue (cyanoacrylate), which is particularly useful in patients with the collateral formation to the right coronary artery in whom ASA is contraindicated. METHODS: In our method left coronary ostium was cannulated with 6-8F guiding catheter. Septal branch was cannulated with a 4F catheter and a microcatheter then cyanoacrylate mixture was instilled into the septal artery. Immediate polymerization prevents the leak into the left anterior descending coronary artery, and also into the right coronary artery (RCA) via septal collaterals. RESULTS: Glue septal ablation (GSA) was performed in 18 patients (6 patients had collateral branches to RCA). Immediately after the procedure peak left ventricular outflow (LVOT) gradient reduced significantly both in cardiac catheterization (65.0 ± 13.8 vs. 14.2 ± 5.7 mmHg, P < 0.001) and Doppler echocardiographic measurements (75.8 ± 19.9 vs. 18.0 ± 9.1 mmHg, P < 0.001). LVOT tract gradient reduction persisted after 6 months follow-up. Septal wall thickness (20.2 ± 3.7 mm vs. 16.5 ± 3.2 mm, P = 0.003) reduced and NYHA functional class (3.1 ± 0.4 vs. 2.2 ± 0.3, P < 0.001) improved. There was no significant complication during the procedure and within 6 months follow-up period. CONCLUSIONS: GSA seems to be an efficient and safe approach to HOCM, especially in patients with the collateral formation. Further experience is needed in order to assess the long-term efficacy and safety of this technique.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
26citationsOpenAlex · cited_by_count (cache / database)
14 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- 2023 2023 ESC Guidelines for the management of cardiomyopathiesCitations 2,640 · OpenAlex
- 2016 Glue septal ablation A promising alternative to alcohol septal ablationCitations 15 · OpenAlex
- 2016 Glue septal ablation A promising alternative to alcohol septal ablationCitations 15 · OpenAlex
- 2016 Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Transcoronary and Endocardial ApproachCitations 9 · OpenAlex
- 2018 Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experienceCitations 6 · OpenAlex
- 2017 Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experienceCitations 6 · OpenAlex
- 2016 A Simple and Inexpensive Option for Nonsurgical Septal Reduction in Hypertrophic Obstructive CardiomyopathyCitations 4 · OpenAlex
- 2016 A Simple and Inexpensive Option for Nonsurgical Septal Reduction in Hypertrophic Obstructive CardiomyopathyCitations 4 · OpenAlex
- 2016 A Simple and Inexpensive Option for Nonsurgical Septal Reduction in Hypertrophic Obstructive CardiomyopathyCitations 4 · OpenAlex
- 2023 Single Center Experience of Percutaneous Septal Ablation in Patients With Hypertrophic Cardiomyopathy With A Novel Agent: PolidocanolCitations 3 · OpenAlex